Welcome to our dedicated page for PRF Technologies Ltd. SEC filings (Ticker: PRFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PRF Technologies Ltd. filings document a foreign private issuer with healthcare and solar analytics operations. Current reports on Form 6-K disclose regulatory and development updates for OcuRing™-K, LayerBio’s sustained-release ocular drug-delivery platform, as well as DeepSolar commercial agreements, SaaS deployments, technical due diligence services, patent-related activity, and business updates tied to the company’s operating platforms.
The filing record also covers capital structure and governance matters, including ordinary-share financing arrangements, registration statement incorporation for Form F-3 and Form S-8 purposes, board and executive changes, committee independence, and share-capital actions. PRF’s annual reporting on Form 20-F provides the broader framework for its business, risk factors, operating results, subsidiaries, and public-company controls.
PainReform Ltd. (PRFX) filed a Form 6-K noting it issued a press release on November 5, 2025 titled “PainReform’s DeepSolar, Developing ‘DeepSolar Predict’ within the NVIDIA Connect Program, Featured in The Market Link’s ‘Watchlist Interview’ and Announces Progress Toward Pilot Projects.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The report is signed by Ehud Geller, Executive Chairman of the Board and Interim Chief Executive Officer.
PainReform Ltd. filed a Form 6-K reporting that on October 1, 2025 it issued a press release announcing its financial results for the six months ended June 30, 2025 and furnished unaudited condensed financial statements and an operating and financial review for that period.
The filing also discloses a board change: Professor Eli Hazum resigned effective September 30, 2025 for personal reasons, expressly not due to any disagreement with management, and Asaf Shavit was appointed to the Board effective immediately; Mr. Shavit is a Certified Public Accountant with 35+ years of audit, tax and financial advisory experience.
PainReform Ltd., an Israel-based company, submitted a Form 6-K as a foreign private issuer. The report notes that on August 19, 2025, the company issued a press release titled “PainReform/DeepSolar Accepted into NVIDIA Connect Program.” The press release is furnished as Exhibit 99.1.
The filing is informational, formally placing this collaboration-related announcement into the company’s official U.S. disclosure record. No financial figures, deal terms, or operational metrics are included in this excerpt.
PainReform Ltd. completed a strategic investment in LayerBio to enter the global cataract surgery market, described in the filing as a $9 billion opportunity, via a non-opiate, non-steroidal postoperative NSAID drug delivery system. The report attaches the press release as Exhibit 99.1 and states the first paragraph of that release is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.
The filing is a disclosure of the investment and the attached press release; it does not provide financial terms, clinical data, or operational results within the text of the Form 6-K itself.